pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·3h ago·1 min read
save

Biopharma job postings rise 15% in Q2 as layoffs fall and M&A activity picks up

Aug 7, 2026·read at BioSpace ↗Positive

The Q2 2026 BioSpace report shows a strengthening biopharma job market, with more openings and fewer layoffs compared with the prior year.

Job postings on BioSpace were up 15% year-over-year and 12% from the previous quarter, marking the third consecutive quarterly gain after 10% and 8% increases in Q4 2025 and Q1 2026.

At least 5,000 pharma positions were listed each month, a level not seen since Q1 2024. Science and research R&D listings topped 3,000 in May and rose to 3,119 in June, while biotech R&D jobs jumped 42% year-over-year, extending a six-month growth streak.

The report also notes a rise in mergers and acquisitions and initial public offerings in the first half of 2026, which the authors view as a positive sign for industry health.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees”

read at BioSpace ↗
1,168 words · retrieved 3h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RISING3LILLY2ELI LILLY COParabilis Medicines
topics
CRO/CDMO

related stories

  • Jul 21Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityBioSpace
  • Jul 20Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic medsFierce Biotech
  • 1h agoEnsoma cuts jobs, narrows focus to lead assetBioSpace
  • 4d agoSTAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricingSTAT
  • Jul 31Lilly and Resilience invest $750M in diabetes and obesity drug device supplyBioSpace